The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Arcellx Inc | COM | 03940C100 | 771,682,600 | 6,720,803 | SH | SOLE | 6,720,803 | 0 | 0 | |||
| Arcus Biosciences Inc | COM | 03969F109 | 678,774,816 | 31,424,760 | SH | SOLE | 31,424,760 | 0 | 0 | |||
| Assembly Biosciences Inc | COM NEW | 045396207 | 125,024,600 | 4,505,391 | SH | SOLE | 4,505,391 | 0 | 0 | |||
| Galapagos NV | SPON ADR | 36315X101 | 501,224,310 | 16,707,477 | SH | DFND | 1 | 16,707,477 | 0 | 0 | ||
| Kyverna Therapeutics Inc | COM | 501976104 | 35,608,407 | 4,126,119 | SH | SOLE | 4,126,119 | 0 | 0 | |||
| Xilio Therapeutics Inc | COM | 98422T100 | 5,469,771 | 650,389 | SH | SOLE | 650,389 | 0 | 0 | |||